S&P 500   3,324.84 (+0.55%)
DOW   27,158.50 (+1.23%)
QQQ   270.97 (+0.22%)
AAPL   437.64 (-0.23%)
MSFT   212.85 (-0.21%)
FB   250.61 (+0.31%)
GOOGL   1,484.41 (+0.75%)
AMZN   3,181.08 (+1.35%)
NVDA   451.66 (+0.57%)
CGC   19.08 (-1.24%)
BABA   263.08 (+0.34%)
TSLA   1,479.00 (-0.54%)
MU   51.21 (-0.18%)
GE   6.16 (+0.33%)
AMD   85.08 (+0.05%)
T   29.89 (-0.40%)
F   6.97 (+1.60%)
ACB   10.59 (-1.30%)
GILD   69.55 (-1.88%)
NFLX   503.98 (-1.11%)
DIS   129.72 (+10.60%)
BAC   25.44 (+1.72%)
BA   171.19 (+3.71%)
S&P 500   3,324.84 (+0.55%)
DOW   27,158.50 (+1.23%)
QQQ   270.97 (+0.22%)
AAPL   437.64 (-0.23%)
MSFT   212.85 (-0.21%)
FB   250.61 (+0.31%)
GOOGL   1,484.41 (+0.75%)
AMZN   3,181.08 (+1.35%)
NVDA   451.66 (+0.57%)
CGC   19.08 (-1.24%)
BABA   263.08 (+0.34%)
TSLA   1,479.00 (-0.54%)
MU   51.21 (-0.18%)
GE   6.16 (+0.33%)
AMD   85.08 (+0.05%)
T   29.89 (-0.40%)
F   6.97 (+1.60%)
ACB   10.59 (-1.30%)
GILD   69.55 (-1.88%)
NFLX   503.98 (-1.11%)
DIS   129.72 (+10.60%)
BAC   25.44 (+1.72%)
BA   171.19 (+3.71%)
S&P 500   3,324.84 (+0.55%)
DOW   27,158.50 (+1.23%)
QQQ   270.97 (+0.22%)
AAPL   437.64 (-0.23%)
MSFT   212.85 (-0.21%)
FB   250.61 (+0.31%)
GOOGL   1,484.41 (+0.75%)
AMZN   3,181.08 (+1.35%)
NVDA   451.66 (+0.57%)
CGC   19.08 (-1.24%)
BABA   263.08 (+0.34%)
TSLA   1,479.00 (-0.54%)
MU   51.21 (-0.18%)
GE   6.16 (+0.33%)
AMD   85.08 (+0.05%)
T   29.89 (-0.40%)
F   6.97 (+1.60%)
ACB   10.59 (-1.30%)
GILD   69.55 (-1.88%)
NFLX   503.98 (-1.11%)
DIS   129.72 (+10.60%)
BAC   25.44 (+1.72%)
BA   171.19 (+3.71%)
S&P 500   3,324.84 (+0.55%)
DOW   27,158.50 (+1.23%)
QQQ   270.97 (+0.22%)
AAPL   437.64 (-0.23%)
MSFT   212.85 (-0.21%)
FB   250.61 (+0.31%)
GOOGL   1,484.41 (+0.75%)
AMZN   3,181.08 (+1.35%)
NVDA   451.66 (+0.57%)
CGC   19.08 (-1.24%)
BABA   263.08 (+0.34%)
TSLA   1,479.00 (-0.54%)
MU   51.21 (-0.18%)
GE   6.16 (+0.33%)
AMD   85.08 (+0.05%)
T   29.89 (-0.40%)
F   6.97 (+1.60%)
ACB   10.59 (-1.30%)
GILD   69.55 (-1.88%)
NFLX   503.98 (-1.11%)
DIS   129.72 (+10.60%)
BAC   25.44 (+1.72%)
BA   171.19 (+3.71%)
Log in

NASDAQ:HRTXHeron Therapeutics Stock Price, Forecast & News

$17.38
+0.48 (+2.84 %)
(As of 08/5/2020 11:53 AM ET)
Add
Compare
Today's Range
$16.87
Now: $17.38
$17.56
50-Day Range
$14.26
MA: $17.35
$21.01
52-Week Range
$9.60
Now: $17.38
$26.81
Volume33,129 shs
Average Volume1.02 million shs
Market Capitalization$1.58 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.7
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron) extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens. The company is also developing CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy; and HTX-011, an investigational, long-acting, and extended-release formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam for post-operative pain management. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
Read More
Heron Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.56 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HRTX
CUSIPN/A
Phone858-251-4400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$145.97 million
Book Value$4.48 per share

Profitability

Net Income$-204,750,000.00
Net Margins-138.31%

Miscellaneous

Employees198
Market Cap$1.58 billion
Next Earnings DateN/A
OptionableOptionable
$17.38
+0.48 (+2.84 %)
(As of 08/5/2020 11:53 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Heron Therapeutics (NASDAQ:HRTX) Frequently Asked Questions

How has Heron Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Heron Therapeutics' stock was trading at $13.64 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, HRTX shares have increased by 27.4% and is now trading at $17.38.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Heron Therapeutics?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heron Therapeutics in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Heron Therapeutics
.

How were Heron Therapeutics' earnings last quarter?

Heron Therapeutics Inc (NASDAQ:HRTX) issued its quarterly earnings data on Wednesday, May, 6th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.65) by $0.08. The biotechnology company earned $25.40 million during the quarter, compared to analyst estimates of $21.23 million. Heron Therapeutics had a negative net margin of 138.31% and a negative return on equity of 56.85%. Heron Therapeutics's quarterly revenue was down 19.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.80) earnings per share.
View Heron Therapeutics' earnings history
.

What price target have analysts set for HRTX?

10 brokers have issued 12-month price objectives for Heron Therapeutics' shares. Their forecasts range from $19.00 to $75.00. On average, they anticipate Heron Therapeutics' share price to reach $38.11 in the next twelve months. This suggests a possible upside of 119.3% from the stock's current price.
View analysts' price targets for Heron Therapeutics
.

What are Wall Street analysts saying about Heron Therapeutics stock?

Here are some recent quotes from research analysts about Heron Therapeutics stock:
  • 1. According to Zacks Investment Research, "Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA. " (5/20/2020)
  • 2. Evercore ISI analysts commented, "We remain highly constructive on the name as ‘011’s differentiated product profile and today’s opioid awareness environment should help propel adoption of the product in a wide range of surgical procedures. We’ve updated the model following earnings; PT remains $75 (OP).  HRTX is confident that the answers to the FDA’s CRL are readily addressed. We will likely see a press release after the NDA is refiled, and the company plans to request a Type A meeting. The key dislocation: the company’s ‘011 timelines have reset, but the commercial opportunity remains unchanged. With the stock trading at these levels, we continue to see substantial upside if the company can execute its launch strategy." (8/13/2019)

Has Heron Therapeutics been receiving favorable news coverage?

News articles about HRTX stock have been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Heron Therapeutics earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the company's share price in the near future.
View the latest news about Heron Therapeutics
.

Who are some of Heron Therapeutics' key competitors?

What other stocks do shareholders of Heron Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Heron Therapeutics investors own include Micron Technology (MU), bluebird bio (BLUE), Gilead Sciences (GILD), Immunomedics (IMMU), Cara Therapeutics (CARA), Amarin (AMRN), Crispr Therapeutics (CRSP), Pfizer (PFE), Seattle Genetics (SGEN) and Inovio Pharmaceuticals (INO).

Who are Heron Therapeutics' key executives?

Heron Therapeutics' management team includes the following people:
  • Dr. Barry D. Quart, Pres, CEO & Director (Age 62)
  • Mr. Robert E. Hoffman C.P.A., CPA, CFO & Sr. VP of Fin. (Age 53)
  • Ms. Kimberly J. Manhard, Exec. VP of Drug Devel. (Age 59)
  • Mr. David L. Szekeres, Sr. VP of Bus. Devel., Gen. Counsel & Corp. Sec. (Age 45)
  • Mr. Sean T. Ristine, VP of HR (Age 49)

What is Heron Therapeutics' stock symbol?

Heron Therapeutics trades on the NASDAQ under the ticker symbol "HRTX."

Who are Heron Therapeutics' major shareholders?

Heron Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Candriam Luxembourg S.C.A. (1.41%), Congress Park Capital LLC (0.22%), Private Asset Management Inc. (0.16%), WINTON GROUP Ltd (0.13%), UBS Group AG (0.13%) and Mackay Shields LLC (0.12%). Company insiders that own Heron Therapeutics stock include Barry D Quart, John Poyhonen, Kevin C Tang, Kimberly Manhard and Waage Christian.
View institutional ownership trends for Heron Therapeutics
.

Which major investors are selling Heron Therapeutics stock?

HRTX stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, SG Americas Securities LLC, UBS Group AG, Dupont Capital Management Corp, and Arizona State Retirement System.
View insider buying and selling activity for Heron Therapeutics
.

Which major investors are buying Heron Therapeutics stock?

HRTX stock was acquired by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Congress Park Capital LLC, WINTON GROUP Ltd, Mackay Shields LLC, Raymond James Financial Services Advisors Inc., Private Asset Management Inc., Diversified Trust Co, and ProShare Advisors LLC. Company insiders that have bought Heron Therapeutics stock in the last two years include Barry D Quart, John Poyhonen, Kevin C Tang, and Waage Christian.
View insider buying and selling activity for Heron Therapeutics
.

How do I buy shares of Heron Therapeutics?

Shares of HRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Heron Therapeutics' stock price today?

One share of HRTX stock can currently be purchased for approximately $17.38.

How big of a company is Heron Therapeutics?

Heron Therapeutics has a market capitalization of $1.58 billion and generates $145.97 million in revenue each year. The biotechnology company earns $-204,750,000.00 in net income (profit) each year or ($2.50) on an earnings per share basis. Heron Therapeutics employs 198 workers across the globe.

What is Heron Therapeutics' official website?

The official website for Heron Therapeutics is www.herontx.com.

How can I contact Heron Therapeutics?

Heron Therapeutics' mailing address is 4242 CAMPUS POINT COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-251-4400 or via email at [email protected]

This page was last updated on 8/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.